XML 52 R42.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Data (Tables)
 9 Months Ended
Jun. 24, 2016
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information by Business Segment
Selected information by business segment was as follows:

Three Months Ended
 
Nine Months Ended

June 24,
2016

June 26,
2015
 
June 24,
2016
 
June 26,
2015
Net sales:



 
 
 
 
Specialty Brands
$
589.3


$
446.2

 
$
1,667.5

 
$
1,154.1

Specialty Generics
263.4

 
307.9

 
785.4

 
954.9

Nuclear Imaging
104.0


108.8

 
309.8

 
320.2

Net sales of operating segments
956.7


862.9

 
2,762.7

 
2,429.2

Other (1)
13.9


14.4

 
40.7

 
35.3

Net sales
$
970.6


$
877.3

 
$
2,803.4

 
$
2,464.5

Operating income:



 
 
 
 
Specialty Brands
$
305.5


$
189.2

 
$
840.6

 
$
434.8

Specialty Generics
101.2

 
157.2

 
321.0

 
501.4

Nuclear Imaging
22.6


23.8

 
68.7

 
47.4

Segment operating income
429.3


370.2

 
1,230.3

 
983.6

Unallocated amounts:





 
 
 
 
Corporate and allocated expenses (2)          
(35.3
)

(71.4
)
 
(110.4
)
 
(210.7
)
Intangible asset amortization
(175.8
)

(149.0
)
 
(524.2
)
 
(396.7
)
Restructuring and related charges, net (3)
(15.3
)

(22.7
)
 
(32.1
)
 
(33.6
)
Non-restructuring impairment charges
—

 
—

 
(16.9
)
 
—

Operating income
$
202.9

 
$
127.1

 
$
546.7

 
$
342.6


(1)
Represents historical CMDS-related intercompany transactions that represent Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.
(2)
Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.
(3)
Includes restructuring-related accelerated depreciation.
Schedule of Net Sales from External Customers by Products
Net sales by product family within the Company's segments are as follows:
 
Three Months Ended
 
Nine Months Ended
 
June 24, 2016
 
June 26, 2015
 
June 24, 2016
 
June 26, 2015
Acthar
$
298.3

 
$
268.7

 
$
833.4

 
$
763.1

Inomax
121.1

 
81.5

 
347.4

 
81.5

Ofirmev
70.7

 
62.1

 
208.7

 
201.6

Therakos immunotherapy
52.5

 
—

 
153.1

 
—

Hemostasis products
13.9

 
—

 
25.3

 
—

Other
32.8

 
33.9

 
99.6

 
107.9

Specialty Brands
589.3

 
446.2

 
1,667.5

 
1,154.1

 
 
 
 
 
 
 
 
Hydrocodone (API) and hydrocodone-containing tablets
38.2

 
37.4

 
115.7

 
138.0

Oxycodone (API) and oxycodone-containing tablets
30.6

 
31.6

 
97.4

 
127.2

Methylphenidate ER
24.3

 
30.0

 
80.1

 
112.6

Other controlled substances
124.7

 
157.4

 
356.3

 
414.7

Other
45.6

 
51.5

 
135.9

 
162.4

Specialty Generics
263.4

 
307.9

 
785.4

 
954.9

 
 
 
 
 
 
 
 
Nuclear Imaging
104.0

 
108.8

 
309.8

 
320.2

 
 
 
 
 
 
 
 
Other (1)
13.9

 
14.4

 
40.7

 
35.3

Net sales
$
970.6

 
$
877.3

 
$
2,803.4

 
$
2,464.5


(1)
Represents historical CMDS-related intercompany transactions that represent Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.